Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Zacks Investment Research downgraded shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a hold rating to a strong sell rating in a research report released on Thursday, Zacks.com reports. According to Zacks, “Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in […]
Accepted 2020-11-12 00:15:19 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-10 Registration Form S-3 Document Format Files Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC… Read More »EFFECT – FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
Los Angeles, CA - (NewMediaWire) - November 02, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceuticals Inc. (“Fennec” or “the Company”) (NASDAQ: FENC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 11, 2020 and August 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before November 2, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 900...